Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 235

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 235
---
 (the “Series B Warrants) at a price of $ 6.895per Pre-Funded Warrant and accompanying Series A and Series B Warrants. The Private Placement closed on September 5, 2024, generating net proceeds to the Company of $ 3,414,502, after deducting placement agent fees and offering expenses.

The September 2024 Pre-Funded Warrants have an exercise price of $ 0.005per share and were immediately exercisable on September 5, 2024 and may be exercised at any time until exercised in full. The Series A and Series B Warrants have an exercise price of $ 6.90per share and were exercisable beginning on the effective date of stockholder approval to approve the issuance of the shares underlying the Series A and Series B Warrants and the September 2024 Agent Warrants, defined below, to comply with applicable listing rules and regulations of the Nasdaq Stock Market (“Stockholder Approval”), which was later received on November 6, 2024 (the “Stockholder Approval Date”). The Series A Warrants expire five years after the Stockholder Approval Date or November 6, 2029, and the Series B Warrants will expire 18 months after the Stockholder Approval Date, or May 6, 2026.

As compensation for acting as the placement agent for the Private Placement, the Company issued to H.C. Wainwright & Co., LLC warrants to purchase up to 43,479shares of stock (the “September 2024 Agent Warrants”). The September 2024 Agent Warrants have substantially the same terms as the Series A Warrants, except that the September 2024 Agent Warrants have an exercise price equal to $ 8.63per share.

The following table presents a summary of the activity for the Company’s equity-classified warrants during the year ended December 31, 2023:

| Total outstanding, December 31, 2022     |     | Number of 
 Warrants  |      - |   |     | Weighted       
 Average        
 Exercise Price |      - |     | Weighted     
 Average      
 Remaining    
 Contractual  
 Life (Years) |    - |
|:-----------------------------------------|:----|:----------|-------:|:--|:----|:---------------|-------:|:----|:-------------|-----:|
| Reclassified from derivative liabilities |     |           |  3,870 |   |     |                |